Management of platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Gynecologic Oncology

Volumn 107, Issue 2, 2007, Pages 211-218

  Havrilesky, Laura J ^a   Secord, Angeles Alvarez ^a   Kulasingam, Shalini ^a   Myers, Evan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness analysis; Ovarian cancer; Platinum sensitive

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GABAPENTIN; GEMCITABINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG SENSITIVITY; HEALTH CARE COST; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RECURRENT CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COSTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; QUALITY OF LIFE; UTERINE CERVICAL NEOPLASMS;

EID: 35348871560     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.06.029     Document Type: Article

References (23)

1. Rose P.G., Fusco N., Fluellen L., and Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 16 4 (1998) 1494-1497
2. Dizon D.S., Hensley M.L., Poynor E.A., Sabbatini P., Aghajanian C., Hummer A., et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 20 5 (Mar 1 2002) 1238-1247
3. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 9375 (Jun 21 2003) 2099-2106
4. Newman G. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit. Lancet 362 9392 (Oct 18 2003) 1333 author reply 4
5. Wheatley K., and Gray R. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit. Lancet 362 9392 (Oct 18 2003) 1333 author reply 4
6. Green J.A. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit. Lancet 362 9392 (Oct 18 2003) 1334 author reply
7. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 29 (Oct 10 2006) 4699-4707
8. Song F., Glenny A.M., and Altman D.G. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 21 5 (Oct 2000) 488-497
9. Rocconi R.P., Case A.S., Straughn Jr. J.M., Estes J.M., and Partridge E.E. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer 107 3 (Aug 1 2006) 536-543
10. Calhoun E.A., Bennett C.L., Peeples P.A., Lurain J.R., Roland P.Y., Weinstein J.M., et al. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol 71 3 (Dec 1998) 369-375
11. Sun C.C., Bodurka D.C., Donato M.L., Rubenstein E.B., Borden C.L., Basen-Engquist K., et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. Gynecol Oncol 87 1 (Oct 2002) 118-128
12. Sun C.C., Bodurka D.C., Weaver C.B., Rasu R., Wolf J.K., Bevers M.W., et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer vol. 13(4) (Apr 2005) 219-227
13. Seltzer V., Vogl S., and Kaplan B. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 21 2 (Jun 1985) 167-176
14. Gershenson D.M., Kavanagh J.J., Copeland L.J., Stringer C.A., Morris M., and Wharton J.T. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 73 5 Pt 1 (May 1989) 798-802
15. Gore M.E., Fryatt I., Wiltshaw E., and Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36 2 (Feb 1990) 207-211
16. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9 3 (Mar 1991) 389-393
17. Pauker S.G., and Kassirer J.P. Decision analysis. N Engl J Med 316 5 (Jan 29 1987) 250-258
18. Ortega A., Dranitsaris G., Sturgeon J., Sutherland H., and Oza A. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 66 3 (Sep 1997) 454-463
19. Neymark N., Gorlia T., Adriaenssen I., Baron B., and Piccart M. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics 20 7 (2002) 485-497
20. Covens A., Boucher S., Roche K., Macdonald M., Pettitt D., Jolain B., et al. Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma?. Cancer 77 10 (May 15 1996) 2086-2091
21. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 22 (Nov 17 2004) 1682-1691
22. Fortner B.V., Schwartzberg L., Tauer K., Houts A.C., Hackett J., and Stolshek B.S. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer vol. 13(7) (Jul 2005) 522-528
23. Gonzalez Martin A.A.C.E., Bover I., Rubio M.J., Arcusa A., Casado A., Ojeda B., et al. Randomised phase II study of carboplatin (C) versus paclitaxel-carboplatin (PC) in platinum-sensitive (PS) recurrent advanced ovarian carcinoma (AOC) with assessment of quality of life (QoL): a GEICO study. Proc Am Soc Clin Oncol 22 (2003)